Valuation: Alkermes plc

Market Cap 8.33B 7.24B 6.75B 6.2B 11.72B 793B 11.85B 79.53B 31.09B 396B 31.29B 30.61B 1,313B P/E 2026 *
-97.5x
P/E 2027 * 68.3x
Enterprise Value 9.08B 7.88B 7.35B 6.75B 12.77B 863B 12.91B 86.63B 33.87B 432B 34.09B 33.34B 1,430B EV / Sales 2026 *
4.97x
EV / Sales 2027 * 4.63x
Free-Float
89.44%
Yield 2026 *
-
Yield 2027 * -
1 day+0.28%
1 week-1.64%
Current month+1.39%
1 month-9.00%
3 months+45.36%
6 months+45.53%
Current year+77.52%
1 week 47.71
Extreme 47.71
50.7
1 month 47.66
Extreme 47.66
55.67
Current year 27
Extreme 27
55.67
1 year 25.16
Extreme 25.165
55.67
3 years 22.01
Extreme 22.01
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 53 01/08/2026
Director of Finance/CFO 53 15/09/2025
Chief Tech/Sci/R&D Officer 58 30/05/2017
Director TitleAgeSince
Chairman 64 01/09/2011
Director/Board Member 74 26/05/2016
Director/Board Member 63 30/03/2018
Date Insider Type Main position Quantity % Market Cap.
3/8/26 Sell

Compliance Officer

-2,034 0.0012%
3/8/26 Fiscal year

Chief Technology Officer

19,000 0.0114%
3/8/26 Fiscal year

Director

133,416 0.0800%
Change 5-day change 1-year change 3-year change Capi.($)
+0.28%-1.64%+86.48%+79.96% 8.33B
-0.14%-3.34%-0.36%+13.34% 48B
+6.03%+5.22%+420.33%+519.87% 41.13B
-2.21%-6.07%+24.87%+5.20% 37.56B
+2.94%-2.25%+6.15%+59.69% 35.91B
+1.98%+4.74%+12.19%+41.37% 29.86B
+0.47%-3.87% - - 16.12B
+0.31%+0.72%+32.99%+122.25% 16.05B
+0.23%+0.50%+3.57%+17.47% 13.76B
-0.98%-12.98%-4.82%-38.09% 12.1B
Average +0.89%-1.79%+64.60%+91.23% 25.88B
Weighted average by Cap. +1.26%-0.95%+82.53%+115.38%

Financials

2026 *2027 *
Net sales 1.82B 1.58B 1.48B 1.36B 2.57B 174B 2.59B 17.42B 6.81B 86.77B 6.85B 6.7B 288B 1.94B 1.69B 1.57B 1.45B 2.74B 185B 2.77B 18.56B 7.26B 92.47B 7.3B 7.14B 306B
Net income -89.92M -78.08M -72.8M -66.87M -126M -8.55B -128M -858M -336M -4.28B -338M -330M -14.17B 120M 104M 97.38M 89.46M 169M 11.44B 171M 1.15B 449M 5.72B 452M 442M 18.95B
Net Debt 744M 646M 602M 553M 1.05B 70.76B 1.06B 7.1B 2.78B 35.37B 2.79B 2.73B 117B 670M 582M 542M 498M 942M 63.73B 953M 6.39B 2.5B 31.86B 2.52B 2.46B 106B
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
04/08/26 USD 49.67 +0.28% 1,430,842
03/08/26 USD 49.53 +1.10% 1,835,762
31/07/26 USD 48.99 -2.08% 1,624,487
30/07/26 USD 50.03 +3.50% 2,303,338
29/07/26 USD 48.34 -4.28% 4,149,635
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
49.67USD
Average target price
56.00USD
Spread / Average Target
+12.74%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock